Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells

Experimental Hematology

Volumn 37, Issue 4, 2009, Pages 450-460

  Muranyi, Andrew L ^a,b   Dedhar, Shoukat ^a,b   Hogge, Donna E ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD135 ANTIGEN; INTEGRIN LINKED KINASE; MIDOSTAURIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; QLT 0267; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW; CANCER CELL CULTURE; CELL DEATH; CELL KILLING; COLONY FORMING CELL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; UBIQUITINATION; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELOID PROGENITOR CELLS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 62149130798     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.01.002     Document Type: Article

References (57)

1. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
2. Grandage V.L., Gale R.E., Linch D.C., and Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, mapkinase and p53 pathways. Leukemia 19 (2005) 586-594
3. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
4. Gari M., Goodeve A., Wilson G., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105 (1999) 894-900
5. El Deiry W.S. Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 3 (2001) E71-E73
6. Romashkova J.A., and Makarov S.S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
7. Chang F., Lee J.T., Navolanic P.M., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
8. Zhao S., Konopleva M., Cabreira-Hansen M., et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18 (2004) 267-275
9. Luo J.M., Yoshida H., Komura S., et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17 (2003) 1-8
10. Zheng R., Levis M., Piloto O., et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103 (2004) 267-274
11. Attwell S., Mills J., Troussard A., Wu C., and Dedhar S. Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell 14 (2003) 4813-4825
12. Wu C. ILK interactions. J Cell Sci 114 (2001) 2549-2550
13. Sakai T., Li S., Docheva D., et al. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev 17 (2003) 926-940
14. Hannigan G., Troussard A.A., and Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5 (2005) 51-63
15. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., and Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 95 (1998) 11211-11216
16. Persad S., Attwell S., Gray V., et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276 (2001) 27462-27469
17. McDonald P.C., Oloumi A., Mills J., et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68 (2008) 1618-1624
18. Troussard A.A., McDonald P.C., Wederell E.D., et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 66 (2006) 393-403
19. Yau C.Y., Wheeler J.J., Sutton K.L., and Hedley D.W. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65 (2005) 1497-1504
20. Birg F., Courcoul M., Rosnet O., et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 80 (1992) 2584-2593
21. Lyman S.D., Brasel K., Rousseau A.M., and Williams D.E. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells 12 (1994) 99-107
22. Lyman S.D. Biology of flt3 ligand and receptor. Int J Hematol 62 (1995) 63-73
23. Rosnet O., Buhring H.J., Marchetto S., et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10 (1996) 238-248
24. Drexler H.G., Meyer C., and Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma 33 (1999) 83-91
25. Kiyoi H., Towatari M., Yokota S., et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12 (1998) 1333-1337
26. Moreno I., Martin G., Bolufer P., et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88 (2003) 19-24
27. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
28. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96 (2000) 3907-3914
29. Brandts C.H., Sargin B., Rode M., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65 (2005) 9643-9650
30. Lisovsky M., Estrov Z., Zhang X., et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 88 (1996) 3987-3997
31. Guan Y., Gerhard B., and Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101 (2003) 3142-3149
32. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 (2002) 433-443
33. Levis M., Tse K.-F., Smith B.D., Garrett E., and Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 98 (2001) 885-887
34. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
35. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
36. Faivre S., Djelloul S., and Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33 (2006) 407-420
37. Park S., Chapuis N., Bardet V., et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22 (2008) 1698-1706
38. Weisberg E., Banerji L., Wright R.D., et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 111 (2008) 3723-3734
39. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
40. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
41. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (1985) 620-625
42. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
43. Kitamura T., Tange T., Terasawa T., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140 (1989) 323-334
44. Ailles L.E., Gerhard B., and Hogge D.E. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 90 (1997) 2555-2564
45. Hogge D.E., Lansdorp P.M., Reid D., Gerhard B., and Eaves C.J. Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood 88 (1996) 3765-3773
46. Valderrama-Carvajal H., Cocolakis E., Lacerte A., et al. Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol 4 (2002) 963-969
47. 2+-independent myosin diphosphorylation and contraction of vascular smooth muscle. Biochem J 392 (2005) 641-648
48. Tan C., Cruet-Hennequart S., Troussard A., et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5 (2004) 79-90
49. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., and Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 108 (2006) 3504-3513
50. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
51. Edwards L.A., Woo J., Huxham L.A., et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther 7 (2008) 59-70
52. Knight Z.A., Chiang G.G., Alaimo P.J., et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12 (2004) 4749-4759
53. Siendones E., Barbarroja N., Torres L.A., et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25 (2007) 30-37
54. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 (2003) 1158-1165
55. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., and Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16 (2002) 1713-1724
56. Tabe Y., Jin L., Tsutsumi-Ishii Y., et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67 (2007) 684-694
57. Pardanani A., and Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104 (2004) 1931-1939